The trials listed below are accepting new patients.  Interested patients can Email the coordinator by clicking on envelope icon. Please include a phone number and best times to call.

Treatment Phase
Short Name
Protocol Title 
ClinicalTrial.Gov link
Penn Research Coordinator
 Am I Eligible?

Newly diagnosed stage 2-4


Letrozole With or Without Paclitaxel and Carboplatin in Treating Patients With Stage II-IV Ovarian or Primary Peritoneal Cancer



Destany Fields 

Eligibility Criteria



Combination ATR and PARP Inhibitor with AZD6738 and Olaparib in Recurrent Ovarian Cancer


Shavon Rochester

Eligibility Criteria

TC 210

 Phase 1/2 Trial of TC-210 T Cells in Patients With Advanced Mesothelin-Expressing Cancer


Katie Elkins

Eligibility Criteria

Enrollment on Hold




A Phase 1 Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of STRO-002, an Anti-Folate Receptor alpha (FolRα) Antibody DrugConjugate (ADC), in Combination with Bevacizumab in Patients with Advanced Epithelial Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers)

NCT05200364 Destany Fields

Eligibility Criteria 

Enrollment on Hold

Recurrent MYTHIC Phase 1 Study of the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Clinical Activity of RP-6306 in Patients with Advanced Solid Tumors (MYTHIC Study) NCT04855656 Andrea Standish, RN Eligibility Criteria 
Recurrent MAGNETIC Phase 1 Study of the PKMYT1 Inhibitor RP-6306 in Combination with Gemcitabine for the Treatment of Advanced Solid Tumors (MAGNETIC Study) NCT05147272 Andrea Standish, RN Eligibility Criteria
Recurrent FAETH A Phase 1b Study of Serabelisib in Combination with an Insulin Suppressing Diet (Study ISD) in Subjects with Advanced Solid Tumors with PIK3CA Mutations with or without PTEN loss NCT05300048 Katie Elkins

Eligibility Criteria

Enrollment on Hold

Recurrent ATRIN A Phase 1/2a, Open-Label, Safety, Pharmacokinetic, and Preliminary Efficacy Study of Oral ATRN-119 in Patients with Advanced Solid Tumors NCT04905914 Andrea Standish, RN  Eligibility Criteria
Recurrent Xencor A Phase 2 Study of XmAb®20717 in Patients With Selected Gynecological Malignancies and High-Risk Metastatic Castration-Resistant Prostate Cancer NCT05032040 Isabel Forbes Eligibility Criteria
Recurrent GOG 3066 A Phase 2 Open-Label, Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer NCT04814108 Kristina Powell Eligibility Criteria 
Recurrent GOG 3063 A Phase 3, Multicenter, Open-Label, Randomized Study of Nemvaleukin Alfa in Combination With Pembrolizumab Versus Investigator’s Choice Chemotherapy in Patients With Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (ARTISTRY-7) NCT05092360 Shavon Rochester Eligibility Criteria
Recurrent STAR-101 A Phase 1 Study of SynKIR-110, Autologous T cells Transduced with Mesothelin KIR-CAR, in Subjects with Mesothelin-Expressing Advanced Ovarian Cancer, Cholangiocarcinoma, or Mesothelioma NCT05568680 Katie Elkins Eligibility Criteria
Recurrent NP-G2-044-P2-01 NP-G2-044 as Monotherapy and Combination Therapy in Patients With Advanced or Metastatic Solid Tumor Malignancies NCT05023486 Shavon Rochester Eligibility Criteria
Surgery CC008 A Non-Randomized Prospective Clinical Trial Comparing the Non-Inferiority of Salpingectomy to Salpingo-Oophorectomy to Reduce the Risk of Ovarian Cancer Among BRCA1 Carriers [SOROCk] NCT04251052 Kristina Powell Eligibility Criteria